At the European Respiratory Society International Congress, it was announced that a pooled analysis of the BOREAS and NOTUS trials showed that dupilumab was effective and safe in adults with moderate to severe COPD and type 2 inflammation at week 52. The study found that patients receiving dupilumab had a lower annualized exacerbation rate and improved lung function compared to those on a placebo. Dupilumab was well-tolerated in this patient population, with similar rates of adverse events reported between the dupilumab and placebo groups. These findings suggest that dupilumab may be a viable treatment option for patients with COPD and type 2 inflammation who continue to experience exacerbations.
Source link
Dupilumab beneficial in COPD with type 2 inflammation
